8-K: Amgen Reports Strong First Quarter 2024 Revenue Growth Driven by Volume and Horizon Acquisition

Amgen's first quarter 2024 results show a 22% revenue increase to $7.4 billion, driven by strong volume growth and the acquisition of Horizon Therapeutics.

Summary

• Amgen's total revenue for the first quarter of 2024 reached $7.4 billion, a 22% increase compared to the same period in 2023.
• Product sales also grew by 22%, with a 25% increase in volume.
• Ten products experienced double-digit volume growth, including Repatha, TEZSPIRE, EVENITY, BLINCYTO, and TAVNEOS.
• The Horizon Therapeutics acquisition contributed $914 million in sales, with key products like TEPEZZA, KRYSTEXXA, and UPLIZNA.
• Excluding Horizon, product sales grew by 6%, driven by a 9% increase in volume.
• GAAP loss per share was $0.21, compared to a GAAP earnings per share of $5.28 in Q1 2023, primarily due to a mark-to-market loss on the BeiGene equity investment and higher operating expenses.
• Non-GAAP EPS decreased by 1% to $3.96, due to higher operating and interest expenses from the Horizon acquisition.
• Free cash flow was $0.5 billion, down from $0.7 billion in Q1 2023, due to an $800 million tax deposit.
• The company has updated its full-year 2024 revenue guidance to a range of $32.5 billion to $33.8 billion.
• Full year 2024 GAAP EPS is projected to be between $7.15 and $8.40, while non-GAAP EPS is expected to be between $19.00 and $20.20.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and volume increases, but tempered by the GAAP loss and decreased free cash flow. The Horizon acquisition is a positive long-term move, but the short-term financial impact is mixed.

Positives

• Amgen experienced strong revenue growth of 22% in the first quarter of 2024.
• Product sales were boosted by a 25% increase in volume, indicating strong demand for their products.
• The acquisition of Horizon Therapeutics added significant revenue, with several of their products performing well.
• Several key products, including Repatha, TEZSPIRE, and EVENITY, showed strong double-digit volume growth.
• The company has a robust pipeline with several programs advancing through clinical trials.
• The company has provided positive full year guidance for 2024.

Negatives

• GAAP earnings per share showed a loss of $0.21, a significant decrease compared to the $5.28 profit in the same quarter of the previous year.
• Free cash flow decreased to $0.5 billion from $0.7 billion in the first quarter of 2023.
• Non-GAAP operating margin decreased by 5.1 percentage points to 43.2%.
• The company experienced a mark-to-market loss on its BeiGene, Ltd. equity investment.
• Operating expenses increased significantly, including higher amortization expenses from Horizon-acquired assets.

Risks

• The company's GAAP results were negatively impacted by a mark-to-market loss on its BeiGene, Ltd. equity investment.
• The integration of Horizon Therapeutics may present challenges and could impact future financial performance.
• The company faces competition from other products, including biosimilars, which could affect sales.
• The company's products are subject to pricing pressure and reimbursement policies.
• The company's research and development activities are subject to regulatory risks and clinical trial uncertainties.
• The company's manufacturing activities are concentrated in a few key facilities, which could pose supply chain risks.
• The company's business may be impacted by government investigations, litigation, and product liability claims.
• The company's stock price is volatile and may be affected by a number of events.

Future Outlook

Amgen expects full-year 2024 total revenues to be in the range of $32.5 billion to $33.8 billion, GAAP EPS to be between $7.15 and $8.40, and non-GAAP EPS to be between $19.00 and $20.20. Capital expenditures are expected to be approximately $1.1 billion, and share repurchases are not to exceed $500 million.

Management Comments

• Robert A. Bradway, chairman and chief executive officer, stated that they are excited about delivering attractive long-term growth with many innovative products delivering strong growth and promising new medicines advancing through the pipeline.

Industry Context

The results reflect the ongoing trend of pharmaceutical companies focusing on innovative products and strategic acquisitions to drive growth. Amgen's acquisition of Horizon Therapeutics is a significant move to expand its portfolio in rare diseases, aligning with the industry's increasing interest in specialized therapies. The strong performance of key products like Repatha and TEZSPIRE also highlights the importance of targeted therapies in the market.

Comparison to Industry Standards

• Amgen's 22% revenue growth in Q1 2024 is strong compared to the average growth rate of large-cap pharmaceutical companies, which typically see single-digit growth.
• The 25% volume growth in product sales is also notable, indicating strong market demand for Amgen's products, which is higher than many of its peers.
• The contribution of $914 million from the Horizon acquisition is significant, demonstrating the impact of strategic acquisitions on revenue growth, similar to other large pharmaceutical companies that have grown through M&A.
• While the GAAP loss per share is concerning, it is primarily due to non-cash items and acquisition-related expenses, which is not uncommon in the pharmaceutical industry after a major acquisition.
• Amgen's non-GAAP EPS of $3.96 is in line with expectations for a company of its size, but the 1% decrease year-over-year indicates the impact of the Horizon acquisition on operating expenses.
• The decrease in free cash flow is also a common trend after a large acquisition, as companies often incur significant integration costs and tax liabilities.
• Compared to companies like AbbVie and Johnson & Johnson, Amgen's focus on innovative therapies and rare diseases is a strategic differentiator, which is reflected in the strong growth of products like TEZSPIRE and TAVNEOS.

Stakeholder Impact

• Shareholders may be concerned about the GAAP loss per share but encouraged by the revenue growth and future guidance.
• Employees may be impacted by the integration of Horizon Therapeutics and ongoing restructuring efforts.
• Customers and patients will benefit from the continued development and availability of innovative medicines.
• Suppliers may see increased demand due to the company's growth and expanded product portfolio.
• Creditors may be reassured by the company's revenue growth but cautious about the increased debt from the Horizon acquisition.

Next Steps

• The company will continue to advance its pipeline programs, including MariTide, tarlatamab, and BLINCYTO.
• The company will present data from several clinical trials at upcoming medical conferences, including ASCO and ATS.
• The company will continue regulatory submissions for key products in various countries.
• The company will initiate a Phase 3 study of TAVNEOS in children with active ANCA-associated vasculitis in H2 2024.
• The company will initiate a Phase 3 study of rocatinlimab in prurigo nodularis in H2 2024.
• The company plans to advance blinatumomab subcutaneous administration through a registration enabling study, with initiation anticipated H2 2024 to H1 2025.

Key Dates

Keywords

Amgen, Horizon Therapeutics, Revenue Growth, Pharmaceuticals, Biotechnology, Product Sales, Clinical Trials, GAAP, Non-GAAP, Earnings, Repatha, TEZSPIRE, Free Cash Flow, Oncology, Rare Disease